DE60325334D1 - Proteinaufreinigung - Google Patents

Proteinaufreinigung

Info

Publication number
DE60325334D1
DE60325334D1 DE60325334T DE60325334T DE60325334D1 DE 60325334 D1 DE60325334 D1 DE 60325334D1 DE 60325334 T DE60325334 T DE 60325334T DE 60325334 T DE60325334 T DE 60325334T DE 60325334 D1 DE60325334 D1 DE 60325334D1
Authority
DE
Germany
Prior art keywords
protein purification
protein
chromatography
washing
solid phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325334T
Other languages
English (en)
Inventor
Robert L Fahrner
Jeffrey R Gorrell
Kathlyn Lazzareschi
Philip M Lester
David Peng
Timothy N Breece
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734396&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60325334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60325334D1 publication Critical patent/DE60325334D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/828—Protein A
DE60325334T 2002-02-05 2003-02-03 Proteinaufreinigung Expired - Lifetime DE60325334D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35457902P 2002-02-05 2002-02-05
PCT/US2003/003097 WO2003066662A2 (en) 2002-02-05 2003-02-03 Protein purification

Publications (1)

Publication Number Publication Date
DE60325334D1 true DE60325334D1 (de) 2009-01-29

Family

ID=27734396

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325334T Expired - Lifetime DE60325334D1 (de) 2002-02-05 2003-02-03 Proteinaufreinigung

Country Status (10)

Country Link
US (2) US6870034B2 (de)
EP (2) EP1472275B1 (de)
JP (2) JP4460302B2 (de)
AT (1) ATE417858T1 (de)
AU (2) AU2003210802B2 (de)
CA (1) CA2473144C (de)
DE (1) DE60325334D1 (de)
DK (1) DK1472275T3 (de)
ES (1) ES2319636T3 (de)
WO (1) WO2003066662A2 (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6870034B2 (en) * 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
CN1802388B (zh) * 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
AU2004265253B2 (en) * 2003-07-28 2011-09-01 Genentech, Inc. Reducing protein A leaching during protein A affinity chromatography
SE0400501D0 (sv) * 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
AU2005241431A1 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
AU2006259298B2 (en) * 2005-06-17 2012-06-14 Wyeth Llc Methods of purifying Fc region containing proteins
CN101511858A (zh) * 2005-07-25 2009-08-19 特鲁比昂药品公司 用于蛋白质解聚的组合物和方法
CA2636109A1 (en) * 2006-01-06 2007-07-19 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
WO2007109163A2 (en) * 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
AU2007227700A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
JP2009532474A (ja) 2006-04-05 2009-09-10 アボツト・バイオテクノロジー・リミテツド 抗体精製
JP5386354B2 (ja) * 2006-09-08 2014-01-15 ワイス・エルエルシー アフィニティークロマトグラフィーを使用するタンパク質精製におけるアルギニン洗浄
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
DK2089429T3 (en) * 2006-10-19 2015-01-12 Janssen Biotech Inc PROCEDURE FOR MANUFACTURING NON-AGGREGATED ANTIBODY-FC DOMAINS
WO2008127305A2 (en) * 2006-11-01 2008-10-23 Biogen Idec Ma Inc. Method of isolating biomacromolecules using low ph and divalent cations
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
AU2008208837A1 (en) * 2007-01-26 2008-07-31 Merck Serono S.A. Purification of Fc-TACT fusion proteins using the oilbody technology
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
EP2209498A2 (de) * 2007-10-03 2010-07-28 Cornell University Behandlung von proliferativen erkrankungen mit psma-antikörpern
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2321422A4 (de) 2008-07-08 2013-06-19 Abbvie Inc Prostaglandin-e2-immunglobuline mit doppelter variabler domäne und verwendungen davon
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CA2911256A1 (en) 2008-10-20 2010-12-09 Robert K. Hickman Isolation and purification of antibodies using protein a affinity chromatography
KR101093717B1 (ko) * 2008-11-26 2011-12-19 한국생명공학연구원 Ｖｅｇｆ―특이적인 인간항체
CA2752510C (en) * 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP2473524A4 (de) * 2009-09-01 2013-05-22 Abbott Lab Immunglobuline mit zweifacher variabler domäne und ihre verwendung
WO2011038894A1 (en) * 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
ES2604103T3 (es) 2009-10-01 2017-03-03 F. Hoffmann-La Roche Ag Filtración final de una preparación de inmunoglobulina en múltiples pasos
PE20121531A1 (es) 2009-10-15 2012-12-22 Abbott Lab Inmunoglobulinas con dominio variable dual
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
PL2513134T3 (pl) 2009-12-18 2018-02-28 Novartis Ag Roztwór do przemywania i sposób chromatografii powinowactwa
DK2526114T3 (da) * 2010-01-22 2014-09-29 Boehringer Ingelheim Int Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
US20120034207A1 (en) * 2010-06-16 2012-02-09 Mclean Michael D Production of her receptor antibodies in plant
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2820095C (en) 2010-12-21 2019-02-26 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
BR112013024933A2 (pt) * 2011-03-29 2016-09-06 Glaxosmithkline Llc sistema tampão para purificação de proteínas
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN107115526A (zh) 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN107840888B (zh) 2011-10-10 2022-03-29 希望之城公司 中间位和中间位结合抗体及其用途
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
EP3501550A1 (de) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2836518B1 (de) * 2012-04-11 2019-01-02 Bioverativ Therapeutics Inc. Verfahren zum nachweis von glykosaminoglykanen
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (de) 2012-07-02 2014-01-08 Millipore Corporation Reinigung biologischer Moleküle
US20150218208A1 (en) 2012-08-27 2015-08-06 Asahi Kasei Medical Co., Ltd. Method for purifying antibody by temperature-responsive chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AR093311A1 (es) 2012-11-01 2015-05-27 Abbvie Inc Inmunoglobulinas de dominio variable dual contra el factor de crecimiento endotelial vascular (vegf) y el ligando involucrado en la señalizacion celula a celula a traves del receptor notch (dll4)
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
EP2931301B2 (de) * 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Verfahren zum reinigen von insulin und analoga davon
CA2902854C (en) 2013-03-08 2024-01-23 Genzyme Corporation Integrated continuous manufacturing of therapeutic protein drug substances
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2015013166A (es) 2013-03-15 2015-12-11 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
WO2014170867A1 (en) 2013-04-18 2014-10-23 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
TW201509432A (zh) 2013-07-05 2015-03-16 Lab Francais Du Fractionnement 親和層析基質
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
CN105722992B (zh) 2013-09-13 2021-04-20 豪夫迈·罗氏有限公司 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015103545A1 (en) 2014-01-03 2015-07-09 Bio-Rad Laboratories, Inc. Removal of impurities from protein a eluates
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
EA201790558A1 (ru) 2014-10-15 2017-08-31 Ксенотера Композиция с пониженной иммуногенностью
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
NZ732628A (en) * 2014-12-22 2019-01-25 Systimmune Inc Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
EP3252158A4 (de) 2015-01-26 2018-07-18 Kaneka Corporation Mutantes immunglobulin-kappa-ketten-bindendes protein mit variabler region
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
MX2017011121A (es) 2015-03-13 2017-11-28 Bristol Myers Squibb Co Uso de lavados alcalinos durante la cromatografia para remover impurezas.
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
WO2017195638A1 (ja) 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
KR102578256B1 (ko) * 2016-08-11 2023-09-15 리플리겐 코포레이션 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질
CN107964044B (zh) * 2016-10-19 2021-11-19 无锡科捷诺生物科技有限责任公司 从乳样中纯化抗cd20单克隆抗体的方法
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3606964A4 (de) 2017-04-03 2020-12-09 Immunomedics, Inc. Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
WO2019036626A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
EP3560945A1 (de) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Verfahren zur reinigung von polypeptiden mit polysorbaten
CA3110666A1 (en) 2018-08-31 2020-03-05 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
US11034774B2 (en) 2018-10-30 2021-06-15 The Regents Of The University Of California Engineered antibodies for the detection of phosphorylated tyrosine
CN113166200B (zh) * 2018-12-21 2024-03-01 上海药明生物技术有限公司 一种提高蛋白a层析法去除聚集体的方法
JP7412440B2 (ja) 2019-03-29 2024-01-12 エフ． ホフマン－ラ ロシュ アーゲー アビド結合多重特異性抗体を作製する方法
AU2020266993A1 (en) 2019-04-30 2022-01-06 Xenothera Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer
AR122270A1 (es) 2019-05-20 2022-08-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
EP4251209A1 (de) 2020-11-24 2023-10-04 Novartis AG Bcl-xl-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
WO2023223097A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody drug conjugates

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
EP0253331B1 (de) * 1986-07-15 1994-10-19 Kowa Co. Ltd. Throminbindende Substanz und Verfahren zu ihrer Herstellung
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0308936B1 (de) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5683916A (en) * 1988-10-31 1997-11-04 Hemasure Inc. Membrane affinity apparatus and purification methods related thereto
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5173408A (en) * 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
ES2296839T3 (es) 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (de) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetisches Bindeprotein für Tumormarker
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
US5726293A (en) * 1992-10-02 1998-03-10 The General Hospital Corporation Affinity purification methods involving imidazole elution
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
ATE157455T1 (de) 1993-12-10 1997-09-15 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
CA2181787A1 (en) 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1516629B1 (de) 1996-11-27 2013-04-03 Genentech, Inc. Humanisierte Antikörper gegen CD-11a
SI1900751T1 (sl) 1996-11-27 2010-03-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
CA2387108A1 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6870034B2 (en) * 2002-02-05 2005-03-22 Genentech, Inc. Protein purification

Also Published As

Publication number Publication date
WO2003066662A3 (en) 2003-12-31
US20030153735A1 (en) 2003-08-14
JP4460302B2 (ja) 2010-05-12
AU2009220025B2 (en) 2011-09-15
EP2048154B2 (de) 2015-06-03
EP1472275B1 (de) 2008-12-17
ATE417858T1 (de) 2009-01-15
ES2319636T3 (es) 2009-05-11
EP2048154A1 (de) 2009-04-15
EP2048154B1 (de) 2012-08-01
EP1472275A2 (de) 2004-11-03
AU2003210802B2 (en) 2009-09-10
US6870034B2 (en) 2005-03-22
AU2003210802A1 (en) 2003-09-02
CA2473144A1 (en) 2003-08-14
EP1472275A4 (de) 2006-02-08
CA2473144C (en) 2013-05-28
JP2005526030A (ja) 2005-09-02
AU2009220025A1 (en) 2009-10-15
JP5097738B2 (ja) 2012-12-12
WO2003066662A2 (en) 2003-08-14
DK1472275T3 (da) 2009-04-14
JP2009196998A (ja) 2009-09-03
US20050215769A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
DE60325334D1 (de) Proteinaufreinigung
WO2004024866A3 (en) Protein purification
WO2003102132A3 (en) Non-affinity purification of proteins
EA200702210A1 (ru) Способ очистки белков
CY1108602T1 (el) Μεθοδος καθαρισμου της fsh
AR010073A1 (es) Purificacion de proteinas.
ATE363491T1 (de) Reinigung von antikörpern durch protein a und ionenaustauschromatographie
DE60206847D1 (de) Verfahren für die Reinigung von Interferon-Proteinen mittels Kationen-Austauschchromatographie
DE69905213D1 (de) Reinigungsverfahren für CO2
EA200601029A1 (ru) Способ очистки фсг
DE50205246D1 (de) Antrieb für Fahrzeughaube
DE60122677D1 (de) Felge für Fahrrad
DE602004022177D1 (de) Reinigung glucagonähnlicher peptide
DK1105508T3 (da) Fremgangsmåde til oprensning af biomolekyle- eller proteinkomplekser
DE60225456D1 (de) Lichteinheit für fahrzeugscheinwerfer
NO20034584L (no) Fremgangsmåte for å konsentrere sulfid
DE60234289D1 (de) Reinigungsverfahren für Zyklohexanonoxim
ATE481408T1 (de) Reinigung von beta-lactam-verbindungen
FR2818629B1 (fr) Procede de purification du soufre
DK1177164T3 (da) Fremgangsmåde til oprensning af diacerein
IS7183A (is) TRK fjölpeptíðhreinsunaraðferð
DE60304435D1 (de) Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
ATE412409T1 (de) Verfahren zur reinigung von pravastatin
PL376745A1 (pl) Proces oczyszczania białek wiążących TNF przy użyciu IMAC
ITMI20031247A0 (it) Processo per la purificazione di gabapentina

Legal Events

Date Code Title Description
8363 Opposition against the patent